Mr. Michael O’Rourke – CEO, Director
Michael O’Rourke, has been involved in “drug delivery” for over 30 years across Ophthalmology, Periodontal and Pulmonary markets including strategy development and global commercialization; previous companies include 3M Pharma, Pfizer, Alza, Chiron Vision, Bausch + Lomb and GrayBug. In 2009 Michael founded Scotia Vision Consultants advising ophthalmic companies on all aspects of commercialization and product development with a focus on anterior and posterior ocular drug delivery
Prior to establishing Scotia Vision Consultant in 2009, Michael was General Manager for the $200m Bausch + Lomb U.S. Pharmaceuticals division in Tampa FL with full P&L and operating responsibility, transforming the business to record levels of growth and managing 150 employees. Previously he pioneered new Bausch + Lomb global strategy divisions including Pharmaceutical, Drug Delivery and Surgical products in California and Rochester NY. Michael was CEO for the start up company GrayBug based in Johns Hopkins University (Baltimore, Maryland) where his accomplishments included the closure of an A2 round, securing 4 SBIR grants totalling $750K, developing an infra structure for business development deals and advancing pre clinical research programs in retina and glaucoma.
His ocular drug delivery experience includes launching the world’s first intra ocular drug delivery technology in Europe, Vitrasert®, and the world’s second, Retisert®, in the USA. Michael was the first European Marketing Director for Chiron Vision Europe. Additional experience includes Alza International (drug delivery) establishing their European division and launching the world’s first sustained release technology Actisite® treating periodontitis. At 3M Michael worked in both sales and marketing for new sustained release therapeutics and enhanced aerosol delivery technologies treating pulmonary disease.
Michael has managed 28 brands, led 13 product launches, structured/negotiated 12 strategic business deals and has been a team member in 18 device/drug approvals. Michael has both presented and published within ophthalmology at congresses and within respected journals. He is past Chairman of The Foundation Board for The Lions Eye Institute, guest speaker on strategic planning at the University of Tampa and was part time marketing lecturer at Trent University in Nottingham, UK.
He is a native of Scotland and has lived and worked in Europe, USA and Asia. In 2010 he became a member of the GlobalScot Business network; assisting Scottish based Life Science companies plan for USA market entry, and was appointed to the Hall of Fame in 2018. He is based in Tampa, FL.
Prof. Clive Wilson – Chief Scientific Officer
Prof. Wilson is Re-Vana’s Chief Scientific Officer (CSO) and Research Professor at Strathclyde University Glasgow Scotland, and serves as Head of the Re-Vana Scientific Advisory Board. Prof. Wilson is a member of Senate of the European Union Federation of Pharmaceutical Sciences and is a member of the core team for the European COST action on gastrointestinal drug absorption. He has pioneered applications of scintigraphy in the study of physiological and patho-physiological effects on drug absorption following oral, nasal, pulmonary and ophthalmic delivery. Prof. Wilson specializes in both large and small molecule ophthalmic drug delivery and has contributed significantly to ocular drug delivery and gastrointestinal science over the past 30 years.
Thakur Raghu Raj Singh, Ph.D – Co-Founder & Technical Director
Dr. Raj Thakur, is a Reader in Pharmaceutics, School of Pharmacy, Queen’s University Belfast. He holds a PhD in Drug Delivery, MSc in Pharmaceutical Sciences and Bachelors in Pharmacy. Dr. Thakur’s research interests are in the design and physicochemical characterisation of advanced polymeric drug delivery systems for ocular applications. His research group has developed novel long-acting technologies including injectable implants, particulate-based systems and pre-formed implantable devices for delivery of a wide range of therapeutics to address ophthalmic conditions. He has authored over 150 scientific publications, including 43 full papers and four books. He has been an invited speaker at a number of national and international meetings. He is currently acting as the Chair for the Ocular Delivery Focus Group, Controlled Release Society and Scientific Advisor to the editors of the J Pharmaceutical Sciences and editorial board member of a number of international journals.
Prof. David Shima – VP R&D
David T. Shima, Ph.D, joined the Re-Vana team in 2021 as Vice President of R&D. Since obtaining his PhD at Harvard, Prof. Shima has become a leading ophthalmology researcher in both academic and biopharma settings, where he has focused for over 30 years on the role of angiogenesis in diseases of the eye. Prof. Shima has worked as a consultant to numerous ocular-focused biopharma companies and has held senior executive roles at Eyetech Pharmaceuticals, Jerini Ophthalmic, Thrombogenics and Roche, where he ran Ophthalmology Research. He has developed and commercialised ground-breaking drugs in ocular diseases whilst also pursuing academic interests as Professor of Translational Vision Research at University College London’s Institute of Ophthalmology.
Rahul Sonawane, Ph.D – Research Fellow
Dr. Rahul Sonawane has a B. Pharm, M.S. in Pharmaceutics, and PhD (Dr. rer. nat.) in Pharmaceutical Technology (Free University Berlin, Germany). Rahul has more than 10 years’ experience working on the development and idealization of Topical, Transdermal, Nasal and Ocular drug delivery systems while working on academic as well as industrial projects. Rahul has expertise in analytical method development, pre-formulation & formulation development, characterization, lyophilisation, stability testing, in vitro and in vivo evaluation of small & large (therapeutic protein) molecules loaded formulations. He has extensive expertise in the development of polymeric nanoparticles, lipidic nanoparticles, hybrid nanoparticles, micro-particles, sustained release solid implants, in-situ forming implants, Gels and Lyophilized formulations. He has authored Indian, UK & PCT patent applications, 2 Original research articles and several Conference posters. He has also served as abstracts reviewer for the Controlled Release Society Conference and co-supervised PhD, Masters and Undergraduate students.
Yujing Wang, Ph.D – Research Fellow
Dr. Yujing Wang has a MS degree in Polymer Chemistry and Physics (Shanghai Jiao Tong University, China) and a PhD degree in Biomedical Engineering (Maastricht University, Netherlands). Yujing has extensive research experience in developing pharmaceutical formulations for controlled/sustained release of small molecule drugs and biologics (e.g. mAbs). She has worked on multiple projects to develop injectable formulations (nano/microparticles) and implants for cancer and ocular drug delivery, as well as devices, such as stents and vaginal rings, for clinical applications. She has developed expertise in polymer characterization/processing, development/validation of drug quantification methods, protein formulations and characterization of drug delivery systems. She has in depth knowledge on various spectroscopy-based analytical techniques, microscopy techniques, cell-based assays and protein analytical methods. She has authored 5 peer-reviewed research papers, and presented (posters and presentations) at several international conferences.
David Waite, Ph.D – Research Fellow
Dr David Waite has a PhD in Ocular Drug Delivery and an MPHARM degree in Pharmacy (Queen’s University Belfast, Northern Ireland). David has significant experience in the development and characterisation of formulations for sustained release of small molecules and proteins to the eye. As part of a 3 year PhD Project he has developed and characterised multiple injectable formulations that form implants in situ, prior to being photocrosslinked, to provide long-term, sustained protein delivery to the posterior segment of the eye. He also has significant expertise in formulation development and characterisation, development and validation of drug quantification methods, protein analytical methods, bioactivity determination and biocompatibility assays. He has authored a review paper on periocular drug delivery, with research papers in the pipeline (subject to patents) and presented posters at several conferences.
Muhammad Faris Adrianto
Mr. Muhammad Faris has an M.Pharm degree in Drug Delivery (Sandwich Airlangga University, Indonesia – Hoshi University, Japan) and will be submitting a PhD thesis in Ocular Drug Delivery. Faris has more than 8 years research experience in protein formulation and characterisation, protein analysis, protein purification, analytical method development (utilising various chromatography techniques), and quality control evaluation of biologics. As part of a PhD project he has developed and characterised formulation of preformed photo-crosslinked intravitreal implant which provide long-term sustained protein delivery to the posterior segment of the eye. He also has extensive knowledge in various imaging techniques, cell-based assays, biochromatography, microbiology analysis and sterilisation studies, immunoassays, and electrophoresis. He has authored 5 peer reviewed research paper and presented at several international conferences.